KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Common Equity: 2019-2025

Historic Common Equity for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $9.6 billion.

  • Royalty Pharma's Common Equity fell 6.22% to $9.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year decrease of 6.22%. This contributed to the annual value of $10.3 billion for FY2024, which is 2.56% up from last year.
  • Royalty Pharma's Common Equity amounted to $9.6 billion in Q3 2025, which was up 1.24% from $9.5 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Common Equity ranged from a high of $10.4 billion in Q3 2022 and a low of $9.5 billion during Q2 2025.
  • For the 3-year period, Royalty Pharma's Common Equity averaged around $9.9 billion, with its median value being $9.8 billion (2023).
  • As far as peak fluctuations go, Royalty Pharma's Common Equity spiked by 37.34% in 2021, and later dropped by 7.98% in 2023.
  • Over the past 5 years, Royalty Pharma's Common Equity (Quarterly) stood at $10.2 billion in 2021, then decreased by 7.06% to $9.5 billion in 2022, then increased by 5.87% to $10.1 billion in 2023, then rose by 2.56% to $10.3 billion in 2024, then decreased by 6.22% to $9.6 billion in 2025.
  • Its last three reported values are $9.6 billion in Q3 2025, $9.5 billion for Q2 2025, and $9.8 billion during Q1 2025.